Viral vector manufacturer Vibalogics adds CEO to lead expansion, COVID-19 response

In the bustling cell and gene therapy space, commercial manufacturing capacity will have a tough time keeping up with the potentially dozens of candidates hitting the market in the coming years, experts say. One German company plans to expand its U.S. footprint to help meet that demand, and it's found the right leader to get it there.

Vibalogics has added Lonza Houston veteran Tom Hochuli as CEO as the German viral vector manufacturer eyes expansion plans stateside, including a new commercial production facility on the East Coast, managing director and former CEO Stefan Beyer said last week.